Histogenics (HSGX) Misses Q4 EPS by 4c

Histogenics (NASDAQ: HSGX) reported Q4 EPS of ($0.63), $0.04 worse than the analyst estimate of ($0.59).

For earnings history and earnings-related data on Histogenics (HSGX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15